Looking to Partner with the World CNS Series?
Following a year of significant pharma acquisitions, approvals of transformative drugs the first of their kind, and a surge of financial backing to bolster innovation in new targets and preclinical pipelines, 2026 is set to continue this momentum, with more companies prioritizing neuroscience drug development than ever before.
If you have relevant capabilities in this space and would like to align your brand with the CNS community, contact us to promote your capabilities through a bespoke commercial package.

Having trouble downloading the brochure? Let us know and we’ll email it to you instead.